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glutamic acid deletion (
 
 
 
E) in the AAA
 
 
 
 protein
torsinA causes DYT1 dystonia. Although the ma-
jority of torsinA resides within the endoplasmic
reticulum (ER), torsinA binds a substrate in the lumen of
the nuclear envelope (NE), and the 
 
 
 
E mutation enhances
this interaction. Using a novel cell-based screen, we iden-
tify lamina-associated polypeptide 1 (LAP1) as a torsinA-
interacting protein. LAP1 may be a torsinA substrate, as
expression of the isolated lumenal domain of LAP1 inhib-
its the NE localization of “substrate trap” EQ-torsinA and
A 
 
EQ-torsinA coimmunoprecipitates with LAP1 to a greater
extent than wild-type torsinA. Furthermore, we identify
a novel transmembrane protein, lumenal domain like
LAP1 (LULL1), which also appears to interact with torsinA.
Interestingly, LULL1 resides in the main ER. Consequently,
torsinA interacts directly or indirectly with a novel class of
transmembrane proteins that are localized in different
subdomains of the ER system, either or both of which may
play a role in the pathogenesis of DYT1 dystonia.
 
Introduction
 
DYT1 dystonia is an autosomal dominant childhood-onset neu-
rological disease characterized by prolonged involuntary twist-
ing movements that reflect neuronal dysfunction rather than
neurodegeneration (Fahn et al., 1987; Berardelli et al., 1998).
The mechanism by which the pathogenic mutation in the
AAA
 
 
 
 protein torsinA produces DYT1 dystonia is unknown
(Ozelius et al., 1997). Because AAA
 
 
 
 proteins are chaperones
that alter the conformation of substrates, the identity of sub-
strate determines the biological pathway modulated by AAA
 
 
 
protein function (Vale, 2000). For example, the role of the
AAA protein NSF in neuronal function is best appreciated
when one considers that it acts upon SNARE complexes.
TorsinA resides in the ER lumen, but several observa-
tions indicate that it interacts with a nuclear envelope (NE)
substrate (for review see Gerace, 2004). In addition, disease-
associated 
 
 
 
E-torsinA accumulates abnormally in the NE,
suggesting that NE dysfunction may contribute to disease
pathogenesis  (Goodchild and Dauer, 2004). Consequently,
identifying a NE substrate of torsinA is likely to further our un-
derstanding of the molecular pathogenesis of DYT1 dystonia.
Because torsinA is expected to alter the conformation of a NE
lumenal protein, characterizing this interaction may also pro-
vide insight into the functional organization of the NE and the
poorly understood roles of NE resident proteins and their asso-
ciated genetic diseases.
 
Results and discussion
 
We have previously shown that, although wild-type (WT)
torsinA is predominantly localized in the main ER, pathogenic
 
 
 
E-torsinA and a predicted “substrate trap” ATP hydrolysis-
deficient EQ-torsinA concentrate in the NE (Fig. 1 A; Vale,
2000; Goodchild and Dauer, 2004). NE resident proteins typi-
cally concentrate in the nuclear membrane through a selective
retention mechanism mediated by binding to the nuclear lamina
(Burke and Stewart, 2002). Consequently, NE proteins are
less mobile in the NE than in the ER membrane (Ellenberg et
al., 1997). If torsinA interacts with a NE protein, it should
therefore display similarly reduced mobility in the NE. We
tested this concept by examining the mobility of torsinA using
FRAP analysis of BHK21 cells transiently overexpressing
GFPWT-, GFP
 
 
 
E-, and GFPEQ-torsinA. At moderate expres-
sion levels, both GFP
 
 
 
E- and GFPEQ-torsinA selectively lo-
calize in the NE (Fig. 1 B); these cells were used for NE FRAP
measurements. Cells expressing higher levels of these proteins
also contain fluorescence in the main ER (Fig. 1 D), allowing
us to perform ER FRAP measurements. In the ER, all three
forms of GFP-torsinA displayed a similar time course of fluo-
rescence recovery (
 
 
 
65% after 210 s; Fig. 1 E). In contrast,
the NE fluorescence recovery of GFP
 
 
 
E- and GFPEQ-torsinA
was markedly slower than GFPWT-torsinA (Fig. 1 C). In the
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NE, only 50% of GFP
 
 
 
E-torsinA and 40% of GFPEQ-torsinA
fluorescence recovered within 330 s (Fig. 1 C), at which time
75% of GFPWT-torsinA fluorescence had returned. However,
it is possible that contaminating fluorescence from ER GFPWT-
torsinA may contribute to an overestimate of NE GFPWT-
torsinA recovery.
The rate of GFPEQ-torsinA FRAP is slower than that
of some well characterized transmembrane NE proteins (such
as emerin), but is comparable to others (Ellenberg et al.,
1997; Östlund et al., 1999; Daigle et al., 2001; Shimi et al.,
2004). Because torsinA is restricted to the ER lumen/perinu-
clear space, it cannot bind to nuclear lamins. Therefore,
these findings are consistent with the hypothesis that the NE
accumulation of 
 
 
 
E-torsinA is caused by an abnormal inter-
action with an immobilized transmembrane substrate. The
rate of GFP
 
 
 
E- and GFPEQ-torsinA fluorescence recovery
is likely to be a function of (a) the degree to which its NE
binding partner is immobilized and (b) the rate at which tor-
sinA cycles on and off this partner. A higher rate of cycling
might explain the faster recovery of GFP
 
 
 
E-torsinA com-
pared with GFPEQ-torsinA.
 
Lamina-associated polypeptide 1 (LAP1) 
is a torsinA binding protein
 
Based on the behavior of WT and mutant torsinA, we next
sought to identify a torsinA NE binding partner. We devel-
oped a screening procedure based on the assumption that over-
expressing a NE-localized torsinA substrate would increase
the amount of torsinA in the NE, which is normally quite low.
We selected candidate proteins that normally reside in the NE
and contain a predicted lumenal domain that is conserved be-
tween mammalian species because these features indicate a
potential functional role within the NE lumen. Cells stably ex-
pressing GFPWT-torsinA (BHK
 
GFPWT
 
; Fig. 1 A) were trans-
fected with 18 candidate protein cDNAs in a reporter plasmid
that coexpresses 
 
 
 
-galactosidase (Table I and Fig. 2 A). Of all
tested NE candidate proteins, only LAP1 recruited GFPWT-
torsinA to the NE in a uniform perinuclear distribution remi-
niscent of substrate trap GFPEQ-torsinA (Table I and Fig.
2 A; compare transfected and untransfected cells). Occasion-
ally, cells expressing high levels of lamin B receptor, LUMA,
and Sun2 contained bright puncta of GFPWT-torsinA. These
puncta were considered to be a nonspecific effect of gross
Figure 1. Pathogenic and substrate trap forms of
torsinA display reduced mobility in the NE. (A)
GFP immunolabeling of BHKGFPWT, BHKGFP E, and
BHKGFPEQ stable cell lines. (B and D) GFP fluores-
cence of BHK21 cells transiently transfected with
GFPWT-, GFP E-, or GFPEQ-torsinA and DsRed
fluorescence of control cells transfected with
DsRed2-ER (CLONTECH Laboratories, Inc.). Images
show representative cells immediately before
(top), immediately after (middle), and 120 s after
(bottom) bleaching a ROI (boxed areas) in the NE
(B) or ER (D). Bars, 10  m. (C and E) Relative fluo-
rescence intensity in the ROI as a function of time
after photobleaching at time point “B” (B, bleach;
see Materials and methods). Points show mean
values and SEM. 
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overexpression because they were randomly located in the NE
and ER. We further examined the LAP1 recruitment of GF-
PWT-torsinA by expressing myc-tagged LAP1 (myc-LAP1) in
BHK
 
GFPWT
 
 cells. As expected, cells expressing myc-LAP1 con-
centrated GFPWT-torsinA in the NE (Fig. 2 B), whereas the un-
related ER chaperone, protein disulphide isomerase (PDI), was
unaltered (Fig. 2 C).
To further assess LAP1 as a torsinA NE binding partner,
we used FRAP to compare the mobility of GFP-LAP1 with
GFPEQ-torsinA. We hypothesized that the FRAP of a torsinA
binding partner should be equal to or less than that of substrate
trap EQ-torsinA. Consistent with this notion, the rates of GFP-
LAP1 and GFPEQ-torsinA NE FRAP are strikingly similar in
the initial recovery period (Fig. 2 E). In later stages, GFP-
LAP1 FRAP plateaus at 
 
 
 
30% recovery, whereas GFPEQ-
torsinA FRAP steadily increases, likely because AAA proteins
containing the Walker B box E/Q mutation typically retain a
low level of residual ATP hydrolysis activity (Whiteheart et al.,
1994). Therefore, the comparative FRAP rates of GFPEQ-torsinA
and GFP-LAP1 are consistent with LAP1 being a NE binding
partner of torsinA. We also tested whether or not GFPEQ-torsinA
coimmunoprecipitates with myc-LAP1. Anti-myc immunopre-
Figure 2. LAP1 recruits torsinA to the NE. (A)
GFPWT-torsinA in BHKGFPWT cells transfected
with different NE proteins. Arrows show trans-
fected GFPWT-torsinA cells expressing candi-
date NE proteins, which were identified by co-
labeling for myc or  -galactosidase reporters
(see online supplemental material for more
details). (B) Immunolabeling of myc-LAP1–
transfected BHKGFPWT cells with anti-myc and
anti-GFP. (C) Immunolabeling of myc-LAP1–
transfected BHK21 cells with anti-myc and
anti-PDI. (D) GFP fluorescence of HeLa cells
transiently transfected with GFPEQ-torsinA
and GFP-LAP1 immediately before (pre-
bleach), immediately after (postbleach), and
at 180 and 360 s after photobleaching in the
ROI (boxed area). (E) Relative fluorescence in-
tensity in the ROI as a function of time after
photobleaching. FRAP analysis was performed
as described in Materials and methods. Points
represent mean and SEM. (F) Coimmunopre-
cipitation of GFPEQ-torsinA with myc-LAP1.
Immunoprecipitations with anti-myc antibody
were performed with whole cell lysates (WCL)
of BHKGFPEQ cells (Cell line: EQ) or BHK21
cells (Cell line: BHK) transfected with myc-
LAP1. Immunoblots of WCL and immunopre-
cipitated proteins were probed with anti-tor-
sinA (top panel) and anti-myc (bottom panel).
GFPEQ-torsinA coimmunoprecipitates with
myc-LAP1 from transfected BHKGFPEQ cells (po-
sition of GFPEQ-torsinA indicated by arrow)
but not in the absence of anti-myc antibody
(second lane), with mock-transfected BHKGFPEQ
cells (third lane), or with myc-LAP1–transfected
BHK21 cells (fourth lane). The position of im-
munoglobulin heavy chains is indicated (Ig,
arrowhead).
 
Table I. 
 
Effect of NE candidate proteins on GFPWT-torsinA
Candidate protein Change in GFPWT-torsinA distribution
 
Emerin None
gp210 None
LAP1 Increased NE labeling
LAP2
 
 
 
None
Lamin B receptor Puncta in ER/NE
LUMA Puncta in ER/NE
MAN1 None
Nesprin-1 None
Nurim None
NET3 None
NET4 None
NET26 None
NET31 None
NET39 None
NET51 None
Sun1 (Unc84A homologue) None
Sun2 (Unc84B homologue) Puncta in ER/NE
UNCL (Unc50 homologue) None
 
BHK
 
GFPWT
 
 cells were transfected with NE resident proteins and transfected cells
were identified by colabeling with antibodies against reporter proteins (see Fig.
2 A). The nuclear envelope transmembrane proteins (NET) are described by
Schirmer et al. (2003) and UNCL by Fitzgerald et al. (2000). See Burke and
Stewart (2002) for descriptions of other candidate proteins. 
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cipitations from lysates of BHK
 
GFPEQ
 
 cells transfected with
myc-LAP1 demonstrated that GFPEQ-torsinA coimmunopre-
cipitates with myc-LAP1 (Fig. 2 F), further supporting the idea
that LAP1 and torsinA interact in the NE.
Next, we examined whether or not the lumenal domain of
LAP1 is responsible for its interaction with torsinA, as pre-
dicted by our model. To explore this question, we tested if the
isolated lumenal domain of LAP1 is capable of altering the
perinuclear subcellular distribution of EQ-torsinA. We gener-
ated myc-tagged constructs containing the LAP1 lumenal do-
main with (myc-210LAP1) or without (myc-240LAP1) the
transmembrane domain (Fig. 3 A; Kondo et al., 2002). As ex-
pected, these fragments fail to concentrate in the NE and in-
stead localize in the main ER (Fig. 3 B, left). Expression of ei-
ther LAP1 lumenal fragment produced a clear redistribution of
GFPEQ-torsinA from the NE to the ER (Fig. 3 B). Myc-
210LAP1 causes a similar redistribution of disease-associated
GFP
 
 
 
E-torsinA (Fig. 3 C), and in all instances we observed
strong colocalization between labeling for GFP and myc (Fig. 3,
B and C). The effect of the LAP1 lumenal domain was specific,
as the lumenal domain of the nucleoporin gp210 (Wozniak and
Blobel, 1992) did not alter the subcellular distribution of
GFPEQ-torsinA (Fig. 3 B, bottom).
These data indicate that LAP1 may be a NE-localized
torsinA substrate. LAP1 was originally identified as the antigen
recognized by a monoclonal antibody generated against puri-
fied rat liver nuclear envelopes (RL13). Three RL13 immu-
noreactive NE proteins were designated LAP1A, B, and C
(with molecular masses of 75, 68, and 55 kD, respectively; Se-
nior and Gerace, 1988). A single exon encodes the entire trans-
membrane and lumenal domains of LAP1 in rat, mouse, and
human, suggesting that LAP1 isoforms vary only in their nu-
cleoplasmic portion. Interestingly, the lumenal domain of hu-
man LAP1 is 86% identical to mouse LAP1, whereas the nu-
cleoplasmic domains exhibit only 46% sequence identity. This
comparison suggests that torsinA interacts with a domain of
LAP1 that has a conserved role in the lumen of the NE.
 
Lumenal domain like LAP1 (LULL1) is a 
novel ER-localized LAP1 homologue
 
Because the LAP1 lumenal domain appears to be a torsinA-
interacting motif, we searched for other proteins containing this
domain by performing a BLAST search of the NCBI database.
This search identified a single novel human cDNA (GenBank/
EMBL/DDBJ accession no. NM_145034) encoding a protein
with a lumenal domain like LAP1, which we named LULL1
(Fig. 4, A and B). The LULL1 gene encodes a protein contain-
ing a single predicted transmembrane domain and appears to
have arisen from a gene duplication event because it is located
adjacent to the LAP1 gene on human chromosome 1q24.
cDNA clones also exist for rat and mouse forms of LULL1,
and the LAP1 and LULL1 genes are also adjacent within these
genomes. In contrast to the conserved lumenal domains of
LAP1 and LULL1, there is significant divergence between the
NH
 
2
 
-terminal regions of these proteins that extend outside of
the secretory pathway (Fig. 4, A and B).
To explore whether or not LULL1 interacts with torsinA,
we isolated a human cDNA that matched the sequence of
NM_145034. Transient transfection of BHK21 cells with myc-
tagged LULL1 generates a protein of 
 
 
 
75 kD that is insoluble
in the absence of detergent but is solubilized by 1% Triton
X-100, suggesting the presence of a membrane spanning do-
main (Fig. 4 C). When NH
 
2
 
- (myc-LULL1) or COOH-terminal
(LULL1-myc)–tagged LULL1 were transfected into BHK21 or
HeLa cells, they colocalized with PDI (Fig. 4 D and not de-
picted for HeLa cells), including in low expressing cells. Like
torsinA, both LAP1 and LULL1 proteins are PNGaseF- and en-
doglycosidase H–sensitive glycoproteins, indicating that they
are retained within the ER system (Fig. 4 E).
We transfected myc-LULL1 into BHK
 
GFPEQ
 
 cells to de-
termine if this ER-localized LAP1 homologue also interacts
with torsinA. Consistent with this notion, myc-LULL1 pro-
duced a clear redistribution of GFPEQ-torsinA from the NE to
the ER and there was strong colocalization between GFP and
myc labeling in transfected cells (Fig. 5 A). We obtained simi-
Figure 3. TorsinA interacts with the conserved
lumenal domain of LAP1. (A) Schematic illus-
tration of LAP1 protein structure and the deletion
mutants used in this study. (B) Immunofluores-
cent labeling of transfected BHKGFPEQ cells with
anti-GFP and anti-myc antibodies. GFPEQ-
torsinA is displaced by either LAP1 lumenal
fragment but not by the lumenal fragment of
gp210. (C) Immunofluorescent labeling of
BHKGFP E cells transfected with myc-tagged
210LAP1 with anti-GFP and anti-myc antibodies. 
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lar results with a LULL1 fragment containing only the trans-
membrane and lumenal domains (208LULL1; Fig. 5 A), con-
firming that this domain is responsible for the effects observed
with full-length LULL1. In addition, GFPEQ-torsinA coimmu-
noprecipitates with myc-LULL1 from lysates of myc-LULL1–
transfected BHK
 
GFPEQ
 
 cells (Fig. 5 B). Together, these results
suggest that LULL1 interacts with torsinA in the main ER.
Like torsinA, LAP1 and LULL1 mRNAs are widely expressed
in both neural and nonneural tissue (Fig. 5 C), which is consis-
tent with the hypothesis that these proteins may be physiologi-
cally relevant interactors of torsinA.
Next, we sought to understand why, if torsinA interac-
tors exist in both the NE and ER, substrate trap EQ-torsinA
appears to localize exclusively to the NE. One important
technical consideration is that the much smaller volume of
the NE, compared with the ER, makes torsinA far easier to
detect in the NE when subcellular localization is assessed by
fluorescence microscopy. In addition, the relative steady-
state levels of torsinA and its interactors will influence the
subcellular localization of torsinA. To assess the relative
steady-state levels of these proteins, we used rabbit poly-
clonal antibodies raised against the mouse forms of LAP1,
LULL1, or torsinA that similarly detect their respective anti-
gens (Fig. 5 D). In NIH-3T3 lysate, these antibodies recog-
nize proteins of the appropriate molecular masses, including
the three previously described isoforms of LAP1 (Fig. 5 E;
Senior and Gerace, 1988). The relative intensity of anti-
LAP1 and anti-LULL1 immunoreactivity suggests that there
is significantly more LAP1 than LULL1 in NIH-3T3 fibro-
blasts (Fig. 5 E). Thus, GFPEQ-torsinA may localize to the
NE in these cells (Fig. 5 F) because there is far more NE
binding partner (LAP1).
To examine whether or not LAP1 and LULL1 may be
torsinA substrates, we compared the interaction of these pro-
teins with WT- and EQ-torsinA. Because AAA
 
 
 
 proteins
typically form high affinity interactions with substrate when
bound to ATP (Vale, 2000), substrates of torsinA will bind
more tightly to EQ-torsinA than the WT protein. We tested if
this was the case for LAP1 and LULL1 by performing im-
munoprecipitations on lysates from LAP1- or LULL1-trans-
fected BHK
 
GFPWT
 
 and BHK
 
GFPEQ
 
 cell lines. GFPEQ-torsinA
readily immunoprecipitated with either LAP1 or LULL1.
However, to detect the association of GFPWT-torsinA with
LAP1 or LULL1, it was necessary to perform immunopre-
cipitations from a much greater amount of protein lysate
(Fig. 5 G, WCL). These data suggest strongly, but do not
prove, that LAP1 and LULL1 are substrates of torsinA; an
adaptor protein could mediate the interaction between tor-
sinA and LAP1 or LULL1.
Several lines of evidence indicate that torsinA has a role
in the NE (Gerace, 2004). We demonstrate that this function of
torsinA may involve an interaction with LAP1, and that the be-
havior of LAP1 is consistent with that of a torsinA substrate
(i.e., it is more tightly associated with EQ- than WT-torsinA).
Although the functional role of LAP1 is poorly understood, it is
known to bind A- and B-type lamins (Senior and Gerace, 1988;
Foisner and Gerace, 1993; Martin et al., 1995). This suggests
that alterations in torsinA function may affect the nuclear lamina,
raising the possibility that DYT1 dystonia shares molecular
abnormalities with diseases that result from laminA mutations
(Burke and Stewart, 2002; De Sandre-Giovannoli et al., 2003).
The fact that alterations in both lamin A and torsinA function
lead to NE morphologic abnormalities is consistent with this
notion (Sullivan et al., 1999; Naismith et al., 2004).
Figure 4. LULL1 is an ER resident protein
with homology to LAP1. (A) The percentage of
amino acid sequence identity of predicted
nucleoplasmic (LAP1), cytoplasmic (LULL1),
and transmembrane and lumenal portions of
human LULL1 and LAP1. (B) CLUSTAL W align-
ment of human LAP1 and LULL1 amino acid
sequences. Asterisk indicates position with
identical amino acid residues, colon indicates
conserved amino acid residues, and period
indicates semi-conserved amino acid residues.
Predicted membrane spanning domains (deter-
mined with TMPred) are shaded and a con-
served potential N-linked glycosylation site is
boxed. (C) BHK21 cells transfected with myc-
LULL1 were lysed in buffer with or without 1%
Triton X-100 and centrifuged to separate ly-
sates into soluble (S) and insoluble (P) fractions.
Immunoblots of equal amounts of soluble and
insoluble fractions were probed with anti-myc
antibodies. (D) BHK21 cells transfected with
myc-LULL1 and LULL1-myc were labeled with
anti-myc and anti-PDI. (E) Immunoblotting of
lysates from BHK21 cells transfected with myc-
LAP1 or myc-LULL1 digested with PNGase F or
endoglycosidase H and probed with anti-myc
antibody. 
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We also identify a novel ER protein, LULL1, that interacts
with torsinA through a region conserved with the LAP1 lumenal
domain; this protein also behaves like a torsinA substrate. The
striking homology between the LAP1 and LULL1 lumenal do-
mains suggests that they are similarly modified by the AAA
 
 
 
chaperone activity of torsinA. In addition, LAP1 and LULL1
share other features. They both contain a single membrane-span-
ning domain and their nucleoplasmic (LAP1) and cytoplasmic
(LULL1) regions are similarly sized. Consequently, these pro-
teins may be engaged in similar roles in the NE and ER and con-
tribute to a biological process that is common to both compart-
ments. In light of the mechanism of AAA
 
 
 
 protein function, our
data suggest that alterations in LAP1 or LULL1 activity may
therefore participate in the pathogenesis of DYT1 dystonia.
 
Materials and methods
 
Cell culture
 
BHK21, NIH-3T3, and HeLa cell lines were cultured using standard condi-
tions (American Type Culture Collection). The generation and character-
ization of BHK
 
GFPWT
 
, BHK
 
GFP
 
 
 
E
 
, and BHK
 
GFPEQ
 
 cells has been described
previously (Goodchild and Dauer, 2004). All cell transfections were
performed using Lipofectamine Plus (Invitrogen) according to the manufac-
turer’s instructions.
 
FRAP
 
The day after transfection, cells were trypsinized and replated at 10–20%
confluence in collagen-coated chambered coverglasses (LabTekII) in Dul-
becco’s minimum essential medium media containing 1% FBS. Immediately
before imaging, this media was replaced with media containing 10 mM
Hepes buffer, pH 7.5. Imaging and photobleaching were performed using
a Plan NEOFLUAR 100
 
 
 
/1.30 oil objective on an inverted confocal micro-
scope (model LSM510 Meta; Carl Zeiss MicroImaging, Inc.). Cells trans-
Figure 5. TorsinA interacts with LULL1. (A) TorsinA interacts with the conserved lumenal domain of LULL1. Immunofluorescent labeling of transfected
BHKGFPEQ cells with anti-GFP and anti-myc antibodies. Full-length LULL1 (top) and the LULL1 lumenal domain (bottom) recruit GFPEQ-torsinA to the ER.
(B) TorsinA coimmunoprecipitates with myc-LULL1. Immunoprecipitations and immunoblotting were performed as in Fig. 2 F except that transfections were
performed with myc-LULL1. Immunoglobulin heavy chains were not visible with the exposure time needed to visualize GFPEQ-torsinA. (C) RT-PCR of mouse
LAP1 and LULL1 from whole tissue RNA. (D) Rabbit polyclonal antibodies against LAP1, LULL1, and torsinA similarly detect their respective antigens.
BHK21 cells were transfected with myc-tagged mouse forms of LAP1, LULL1, and torsinA; and WCL was probed with anti-myc to confirm that similar
amounts of transfected protein were loaded (top panel). Immunoblots were subsequently probed (bottom panel) with anti-LAP1, anti-LULL1, and anti-torsinA
at concentrations that generated similar levels of immunoreactivity. Comparative images are from a simultaneous exposure of a single immunoblot.
(E) Immunoblots of NIH-3T3 WCL probed with rabbit polyclonal antibodies. 15  g of 1% SDS NIH-3T3 WCL were probed with rabbit polyclonal antibodies
at the concentrations used in D. Images are from a simultaneous 2-s exposure of a single immunoblot. (F) NIH-3T3 cells transfected with GFPWT-torsinA
(left) or GFPEQ-torsinA (right) and labeled with anti-GFP. (G) LAP1 and LULL1 interact more strongly with substrate trap EQ-torsinA. WCL were prepared
from BHKGFPWT cells (Cell line: WT) and BHKGFPEQ cells (Cell line: EQ) transfected with myc-LAP1 (Tfct: LAP1) or myc-LULL1 (Tfct: LULL1). Proteins were immuno-
precipitated from WCL with anti-myc antibody, eluted from protein G agarose beads and immunoblotted. Parallel control precipitations were performed in
the absence of anti-myc antibody. Immunoblots of immunoprecipitated proteins and 2% of WCL were probed with anti-torsinA and anti-myc. WCL from
BHKGFPWT cells contained more GFP-torsinA, myc-LAP1, and myc-LULL1 than BHKGFPEQ cells because this was necessary to visualize coprecipitated GFPWT-
torsinA. The position of the 65-kD GFP-torsinA is indicated by an arrow (top). Neither myc-LAP1, myc-LULL1, or GFP-torsinA proteins were immunoprecipitated
in the absence of anti-myc antibody. 
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fected with GFP fusion proteins were imaged with 488-nm light, DsRed with
516-nm light, using 2% laser power and a pin hole of 1 airy unit. After two
imaging scans, a selected area of the ER or NE (region of interest [ROI])
was bleached using maximal laser power for 20 iterations, and then the
photobleached cell was imaged at 15-s intervals for 3–6 min. Collected im-
ages were analyzed in Adobe Photoshop to calculate the mean fluores-
cence intensity in the ROI as a function of time after photobleaching. To cor-
rect for whole cell photobleaching caused by the bleaching pulse and
image capture, fluorescence intensity was also measured in an unbleached
area (UA) at all time points and a fractional correction calculated as UA
 
t
 
 
 
n
 
/
UA
 
PB
 
. ROI fluorescence intensity at each time point was corrected by these
values and then normalized so that the prebleach fluorescence level
equaled 100 and immediate post-bleach level was zero.
 
Immunolabeling
 
Immunofluorescence labeling was performed on cells 48 h after transfec-
tion using methanol-fixed cells grown on collagen-coated glass coverslips
(Carolina Scientific). Coverslips were blocked for 1 h at RT in block solu-
tion (PBS, 0.25% Triton X-100 and 10% normal donkey serum), incubated
overnight at 4
 
 
 
C in primary antibodies diluted in block solution. The
next day coverslips were washed, incubated with secondary antibodies
(diluted in block solution), and washed in PBS before mounting using
Vectashield Mounting Media with DAPI (Vector Laboratories). In double la-
beling experiments, GFP was detected with FITC- and myc with Texas red–
conjugated secondary antibodies to minimize the possibility of “bleed
through.” Digital Images were acquired using a laser scanning confocal
microscope (model LSM510 Meta; Carl Zeiss MicroImaging, Inc.). FITC
and Texas red images were acquired successively and figures were pre-
pared in Adobe Photoshop.
 
Antibodies
 
Antibodies used were as follows: affinity purified rabbit polyclonal anti-
torsinA raised against residues 319–332 of mouse torsinA (a gift from B.
Lauring, Columbia University, New York, NY), rabbit polyclonal anti-LAP1
raised against residues 463–478 of mouse LAP1 (Covance Research
Products), and rabbit polyclonal anti-LULL1 raised against residues 107–
120 of mouse LULL1 (Covance Research Products). Other antibodies were
rabbit anti-GFP 1:1,000 (AbCam), mouse anti–
 
 
 
 galactosidase 1:100
(Sigma-Aldrich), mouse anti-myc 1:500 (CLONTECH Laboratories, Inc.),
rabbit anti-myc 1:100 (Sigma-Aldrich), and mouse anti-PDI 1:100 (Stress-
Gen Biotechnologies). All secondary antibodies were raised in donkey
from Jackson ImmunoResearch Laboratories.
 
Immunoprecipitation
 
Immunoprecipitations were performed at 24 h after transfection using
mouse monoclonal anti-myc (CLONTECH Laboratories, Inc.) and Agarose
Protein G immunoprecipitation kit (Roche) according to the manufacturers’
instructions, except that buffers contained only Igepal CA630.
 
LULL1 characterization
 
The solubility of LULL1 was investigated by lysing myc-tagged LULL1-trans-
fected BHK21 cells in buffer (50 mM Tris-HCl, pH 7.5, and protease inhib-
itors) with and without 1% Triton X-100. Homogenates were incubated on
ice for 20 min and centrifuged at 20,000 
 
g
 
 for 15 min to separate super-
natant and pellet fractions. Pellets were solubilized by heating to 95
 
 
 
C in
180 
 
 
 
l of 1
 
 
 
 lamaeli sample buffer. Supernatants were also brought to a
180-
 
 
 
l volume and 1
 
 
 
 concentration. Equal volumes of pellet and super-
natant fractions were used in SDS-PAGE. The glycosylation state of myc-
tagged LAP1 and LULL1 was examined by digesting lysates from trans-
fected BHK21 cells with PNGaseF or Endoglycosidase H (New England
Biolabs, Inc.) according to the manufacturer’s instructions.
 
RT-PCR
 
Total RNA was prepared from mouse tissues using Trizol reagent (Invitro-
gen), and cDNA was generated from 1 
 
 
 
g of total RNA with oligo dT
primers and SuperScript III (Invitrogen), all according to the manufac-
turer’s instructions. Normalization of samples was performed by increas-
ing or decreasing the amount of template cDNA dependent on amplifica-
tion efficiency determined using GAPDH primers. Primers were designed
to amplify cDNA regions that spanned at least one intron boundary, along
with the lumenal domain of LAP1 and LULL1, to prevent amplification from
genomic DNA.
 
Online supplemental material
 
Details of plasmid construction for the candidate cDNA screen, primer de-
tails, and the generation of LAP1 and LULL1 fusion and truncated con-
structs is contained in the online supplemental material. Online supple-
mental material is available at http://www.jcb.org/cgi/content/full/
jcb.200411026/DC1.
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